University of Melbourne
219
49
61
108
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
1.8%
4 terminated/withdrawn out of 219 trials
96.4%
+9.9% vs industry average
19%
41 trials in Phase 3/4
7%
8 of 108 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (219)
ROADMAP Clinical Trial
Role: collaborator
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Role: collaborator
Mobilizing Hispanics With Knee Osteoarthritis
Role: collaborator
Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough
Role: collaborator
Remote Monitoring for Patients With Aortic Stenosis
Role: collaborator
Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)
Role: collaborator
Tranexamic Acid to Reduce Blood Loss After Varus Derotation Osteotomy
Role: collaborator
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
Role: collaborator
Implementing Surgery School Prehabilitation Using Telehealth
Role: lead
Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.
Role: collaborator
Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke
Role: lead
SOS for Caregiver Wellbeing
Role: collaborator
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Role: collaborator
Cross Bracing Protocol Versus Surgery for Acute Anterior Cruciate Ligament Rupture
Role: lead
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Role: lead
Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)
Role: lead
Staphylococcus Aureus Network Adaptive Platform Trial
Role: lead
Exclude or Expose in Irritable Bowel Syndrome: What Works for Whom and How?
Role: lead
Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke
Role: lead
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes
Role: collaborator